Ozempic Stomach Paralysis has recently gained attention due to its association with the use of the medication Ozempic.
It’s a severe condition that affects the normal functioning of the stomach. It is characterized by the slowing down or partial paralysis of the stomach muscles, leading to delayed gastric emptying or gastroparesis.
This condition can cause a range of symptoms, including nausea, vomiting, bloating, stomach pain, and a feeling of fullness even after consuming small amounts of food.
The use of the medication Ozempic has been linked to the development of gastroparesis and subsequent Ozempic Stomach Paralysis.
What was Ozempic’s Original Primary Use?
Ozempic is a medication prescribed to individuals with type 2 diabetes to help manage their blood sugar levels. However, more recently, some individuals have been prescribed this drug to help them lose weight.
In the past few years, several lawsuits have been filed against the manufacturer of Ozempic, alleging that the medication fails to adequately warn patients about the risk of developing gastroparesis.
If you or a loved one has suffered from Ozempic’s stomach paralysis, it is crucial to understand your legal rights and options.
You need to understand the causes of Ozempic’s stomach paralysis, the compensation you may be entitled to, and why it’s in your best interest to have an experienced Ozempic stomach paralysis attorney from our firm on your side.
At Dolman Law Group Injury Lawyers, we have served over 40,000 clients and have a wealth of experience handling complicated personal injury cases, including those involving pharmaceutical negligence.
Schedule A Free Consultation
Table of Contents
- What was Ozempic's Original Primary Use?
- Ozempic Lawsuit Update
- Latest Developments in Ozempic Lawsuits
- Why Choose Our Ozempic Stomach Paralysis Lawyers?
- What Is Ozempic Stomach Paralysis?
- Ozempic Stomach Paralysis Compensation
- Factors that Determine the Value of Your Claim
- What Causes Ozempic Stomach Paralysis
- What Is Pharmaceutical Negligence?
- Why Is Ozempic Being Sued for Failing to Warn About Gastroparesis?
- Who Qualifies to File an Ozempic Lawsuit?
- Fighting for Compensation After Suffering Ozempic Stomach Paralysis
- What to Do After Sustaining Ozempic Stomach Paralysis Injuries
- Were You Told You Have Ozempic Stomach Paralysis? Consult Dolman Law Group Injury Lawyers Today
Ozempic Lawsuit Update
We aim to provide the most up-to-date coverage of the various stomach paralysis lawsuits progressing through the courts.
To file an Ozempic lawsuit, visit our Ozempic Lawsuit page. We will keep it updated with all the latest Ozempic news and developments.
Latest Developments in Ozempic Lawsuits
April 1, 2025–Ozempic Stomach Paralysis Lawsuits: Legal Updates and Case Developments
Patients who developed gastroparesis (stomach paralysis) after using Ozempic and similar GLP-1 drugs have filed lawsuits against Novo Nordisk and Eli Lilly, alleging the companies failed to warn about severe gastrointestinal risks. These cases have been consolidated into a federal multidistrict litigation (MDL No. 3094) in the Eastern District of Pennsylvania, overseen by Judge Karen Marston.
Legal Arguments and Challenges
Defendants filed a motion to dismiss most claims, arguing that plaintiffs lack valid causes of action for fraud, negligent misrepresentation, or design defects aside from failure-to-warn allegations. Plaintiffs countered that the drug manufacturers marketed Ozempic as a weight-loss solution while downplaying serious side effects. A decision on this motion is pending.
Additionally, a significant evidentiary hearing is scheduled for May 2025 to determine whether expert testimony can establish a scientifically reliable link between Ozempic and gastroparesis. This ruling could determine the viability of many claims moving forward.
Disputes Over Proof of Injury
One of the most contentious issues in the litigation is whether plaintiffs must provide specific medical tests to prove they developed gastroparesis. Eli Lilly has requested that the court require a gastric emptying study for any gastroparesis claim, arguing that symptoms alone are insufficient evidence. Plaintiffs’ attorneys argue that real-world medical diagnoses are often based on symptoms and clinical evaluations rather than a single test, and imposing such a requirement could unfairly exclude legitimate claims.
Bellwether Trials and Settlement Possibilities
While the litigation remains in its early stages, the court is working on streamlining the process for new plaintiffs. Bellwether trials—test cases that help gauge potential jury responses—are not expected until 2026. These trials will be key in determining whether the defendants pursue settlement discussions.
Other Emerging Ozempic Side Effects
Beyond gastroparesis, lawsuits and regulatory scrutiny have raised concerns about additional health risks associated with Ozempic and similar drugs:
- Gallbladder Disease – Rapid weight loss has been linked to gallstone formation and gallbladder inflammation, leading some users to require emergency surgery.
- Thyroid Cancer – A recent study suggested a possible increased risk of thyroid cancer in Ozempic users, though further research is needed.
- Mental Health Effects – There have been reports of depression and suicidal thoughts, though current research has not established a direct causal link.
Off-Label Use and Allegations of Overpromotion
Many plaintiffs argue that Novo Nordisk and Eli Lilly aggressively promoted Ozempic for weight loss despite it being FDA-approved only for diabetes. The lawsuits claim this off-label marketing contributed to widespread use among individuals who may not have been adequately monitored for potential risks.
Seeking Compensation for Ozempic-Related Injuries
Individuals who have suffered from gastroparesis or other serious complications after taking Ozempic may be eligible to file a lawsuit. These claims seek compensation for medical expenses, lost quality of life, and long-term suffering. As the MDL progresses, the court’s rulings on key issues—such as causation and required proof of injury—will shape the future of the litigation.
If you or a loved one experienced severe gastrointestinal issues after using Ozempic, legal options may be available. Contact Dolman Law Group to discuss your case.
March 1, 2025–Update on Ozempic Stomach Paralysis Litigation
Growing Number of Cases in MDL No. 3094
Lawsuits against Novo Nordisk over Ozempic-induced gastroparesis (stomach paralysis) continue to increase. In January 2025 alone, 110 new cases were filed, more than tripling the 31 filed in December. As of March 2025, approximately 1,443 lawsuits are pending in MDL No. 3094 in the Eastern District of Pennsylvania.
Nearly 95% of Ozempic-related cases involve gastroparesis, with plaintiffs alleging chronic nausea, persistent vomiting, severe dehydration, and intestinal blockages. Many cases describe emergency hospitalizations and long-term digestive complications. For instance, a Michigan woman’s recent lawsuit claims Ozempic caused debilitating vomiting, extreme constipation, and dehydration, requiring medical intervention.
Recent Court Motions and Legal Developments
- Motion to Dismiss Peripheral Claims (January 2025): Novo Nordisk and Eli Lilly filed a motion to dismiss secondary claims, including breach of warranty, fraud, design defect, negligence, and medical monitoring, arguing they lack legal merit. The core failure-to-warn claims, central to the litigation, were not challenged.
- Plaintiffs’ Response: Attorneys argue that Novo Nordisk misled doctors and patients about the risks of GLP-1 drugs, withholding critical safety data. Plaintiffs contend the attempt to dismiss peripheral claims is a minor issue that won’t impact the core failure-to-warn arguments, which remain strong.
MDL Pretrial Updates and Daubert Hearing Scheduled
A February 24, 2025, status conference addressed procedural matters, including the adoption of short-form complaints, discovery coordination, and deposition protocols.
A key evidentiary hearing is set for May 14, 2025, under Federal Rule of Evidence 702 (Daubert hearing) to assess the scientific validity of expert testimony linking Ozempic to gastroparesis. If plaintiffs’ experts survive this challenge, their case will be strengthened.
No Settlements or Resolution Efforts Yet
There have been no settlement discussions or mediation efforts in the past 30 days. Early settlement talks remain unlikely, with bellwether trials not expected until late 2026 or 2027. Plaintiffs’ attorneys continue recruiting and filing cases, while Novo Nordisk denies liability and seeks to limit litigation scope.
Regulatory Updates: FDA Expands Safety Warnings
On February 20, 2025, the FDA updated Ozempic’s prescribing information, adding stronger warnings about:
- Severe pancreatitis, including rare hemorrhagic and necrotizing cases
- Acute kidney injury linked to dehydration from vomiting or diarrhea
While gastroparesis is not explicitly listed, these warnings support claims that GLP-1 drugs carry serious, underreported risks.
Thyroid Cancer Study Raises Questions
A January 2025 study in JAMA Otolaryngology found a short-term increase in thyroid cancer diagnoses among GLP-1 users. However, after a longer follow-up (up to eight years), no significant difference in thyroid cancer risk was found between GLP-1 users and those on other diabetes medications. Researchers suggest increased monitoring of Ozempic patients, rather than the drug itself, may explain the early spike in cases.
Outlook for the Litigation
With cases continuing to mount, pretrial proceedings advancing, and scientific scrutiny increasing, the litigation remains in its early but rapidly growing phase. The May 2025 Daubert hearing will be pivotal, shaping how the court evaluates medical evidence linking Ozempic to gastroparesis. Settlement discussions remain distant, but regulatory actions and emerging scientific data may influence future case outcomes.
Litigation involving GLP-1 receptor agonists, including Ozempic, continues to grow. As of February 2025, 1,331 personal injury lawsuits have been filed under MDL 3094 in the Eastern District of Pennsylvania. These cases claim that Ozempic and similar drugs have led to severe gastrointestinal complications, including gastroparesis, ileus, and intestinal blockages.
Individuals who have suffered serious side effects from Ozempic or other GLP-1 receptor agonists may be eligible to join the ongoing litigation. Consulting an experienced attorney can help determine the best course of action.
As of January 2025, the multidistrict litigation (MDL) involving Ozempic and other GLP-1 receptor agonists has escalated to 1,300 active cases. This surge includes 79 new lawsuits filed in November, emphasizing a growing wave of plaintiffs who allege serious gastrointestinal complications, such as gastroparesis, caused by these medications. In a pivotal move, the presiding judge issued a scheduling order on December 3, 2024, outlining deadlines for motions to dismiss filed by the defendants. This procedural step allows both sides to argue the legal merits of the claims and sets the stage for further litigation.
Beyond gastrointestinal concerns, recent large-scale studies conducted by the University of Southern Denmark (SDU) have intensified safety worries about Ozempic. The studies uncovered a potential link between the drug and non-arteritic anterior ischemic optic neuropathy (NAION)—a rare but irreversible eye condition that can lead to significant vision loss. Analyzing health data from over 424,000 patients with type 2 diabetes, researchers determined that Ozempic more than doubles the risk of developing NAION. Unlike an earlier U.S. study, which faced limitations due to sample size, the Danish research utilized comprehensive national health registries, providing more credible evidence supporting a causal relationship.
Researchers also observed a notable increase in NAION cases in Denmark following Ozempic’s introduction in 2018, adding weight to ongoing safety concerns. While NAION remains an uncommon side effect, the latest findings could influence prescribing practices, spur regulatory reviews, and impact the trajectory of current lawsuits. These developments underscore the importance of continued monitoring and legal scrutiny surrounding Ozempic and similar medications.
The introduction of supplements like Replenza, formulated to counteract the side effects of Ozempic and other GLP-1 medications, underscores the significant health concerns associated with these drugs. Conditions such as “Ozempic face,” characterized by rapid loss of skin elasticity, gastrointestinal issues, and even personality changes, have led to the development of products to mitigate these adverse effects.
The availability of such supplements highlights the potential risks of using Ozempic, prompting questions about its safety and long-term implications. Individuals should consult healthcare professionals to fully understand these risks before initiating treatment.
Amid rising concerns about serious side effects like stomach paralysis and digestive issues, some Ozempic users are experimenting with micro-dosing—taking very low doses—to reduce side effects such as stomach paralysis or save on prescription costs. However, doctors warn against this practice due to a lack of research on how Ozempic performs at lower doses. Studies have found that people often don’t experience the same weight loss benefits with reduced doses, and side effects, including severe nausea or stomach issues, don’t always decrease with smaller amounts.
Many users access microdoses through compounded versions of Ozempic from specialized pharmacies, but the FDA warns that compounded drugs aren’t approved in the same way as standard prescriptions. Up to 40% of online pharmacies selling compounded Ozempic in 2023 were flagged as potentially illegal, raising concerns about quality and authenticity. Given these risks, doctors advise a qualified healthcare professional to oversee any micro-dose attempt.
New research published in JAMA Network Open has uncovered a potential benefit of semaglutide (Ozempic or Wegovy), a drug typically prescribed for type 2 diabetes and weight loss. The study suggests that semaglutide could lower the risk of opioid overdose for individuals with both type 2 diabetes and opioid use disorder. Compared to those using other diabetes medications, patients taking semaglutide had a notably reduced risk of opioid overdose. This finding is generating interest in whether the drug could play a role in addressing the ongoing opioid crisis.
However, while these results are promising, they also raise concerns about the possible misuse of the drug. If individuals start taking semaglutide, believing it will protect them from opioid overdoses, it could lead to riskier behaviors or more severe addiction issues. Additionally, semaglutide is already involved in numerous lawsuits related to severe side effects like gastroparesis and other gastrointestinal problems. Expanding its use to address opioid overdose could lead to an increase in legal claims, particularly if patients experience unexpected side effects or use the drug for reasons beyond its approved indications.
Given these developments, this information could be essential to ongoing discussions about the risks and legal challenges surrounding semaglutide. It highlights both the evolving uses of the drug and the increasing potential for litigation as its application expands into areas such as opioid overdose prevention.
Researchers reviewed World Health Organization data and published their study results in the JAMA Network last month. The study revealed a strong signal of increased suicidal thoughts among patients who take semaglutide drugs, like Ozempic and Mounjaro, in combination with other medications, including antidepressants. While more evidence is likely needed to support a label warning or the basis of lawsuits, this research supports the frightening possibility that these drugs may cause even more severe problems than we already understand.
The next court appearance for the MDL was set for September 16th, but it has been rescheduled to September 23rd. In the meantime, the plaintiff’s counsel is asking to include the discovery of the defendants’ marketing tactics and whether they are downplaying or negating the actual risks these drugs pose.
The drug manufacturer defendants in this litigation are pushing for expedited discovery and a quick decision about important legal issues. The cross-cutting legal issues include whether Ozempic and similar drugs can be linked to gastroparesis and other medical conditions without an objective diagnostic test and the adequacy of the warning labels on these drugs. The defendants’ goal is to end this MDL quickly, with limited discovery on these issues. Although they are now on the defensive, the plaintiffs are fighting back.
Lawyers for the injured plaintiffs argue all relevant evidence must be examined according to the Bradford Hill criteria. This criterion establishes principles to help decide if there is a causal relationship between a disease and a specific factor, such as a drug. In this MDL, the court will use these guidelines to determine whether Ozempic can be causally linked to health conditions like stomach paralysis,
The plaintiffs are requesting full discovery without shortcuts to ensure a complete analysis of the evidence needed to make these important decisions. At the same time, this MDL has grown from 346 lawsuits on August 1st to 869 claims today.
By September 2024, 257 new lawsuits have been initiated against Novo Nordisk and Eli Lilly in the U.S. District Court for the Eastern District of Pennsylvania. These additional claims, which focus on personal injury and product liability, underscore the ongoing concerns related to the use of medications such as Ozempic, Wegovy, and Mounjaro, suggesting these drugs may still present significant risks to users.
These lawsuits are part of a larger multidistrict litigation (MDL No. 3094) that consolidates personal injury claims against the makers of glucagon-like peptide-1 (GLP-1) receptor agonists. These medications, including Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro, are primarily prescribed for managing type 2 diabetes and aiding in weight loss. Judge Karen Spencer Marston is overseeing the cases. Currently, the MDL comprises 842 cases, with expectations that the total will rise significantly.
In a recent Case Management Order, the court identified three critical issues, known as “cross-cutting” topics, pertinent to many of the cases within this MDL. These issues are:
- Gastroparesis Diagnosis: The court is prioritizing early legal proceedings on whether gastroparesis—a condition in which the stomach fails to empty correctly—can be accurately diagnosed without using objective tests like a gastric emptying study. This determination is crucial, as the inability to reliably diagnose this condition could limit the number of viable claims.
- Federal Preemption and Warning Labels: The court also addresses whether the plaintiffs’ claims are overridden by federal law, particularly concerning the adequacy of FDA-approved warning labels on these drugs. This issue will explore whether these labels sufficiently warned of potential risks, such as gastrointestinal complications, including gastroparesis. The outcome could significantly affect the strength of many cases within the MDL.
- General Causation: The court has delayed its decision on whether the GLP-1 drugs are capable of causing the alleged injuries, pending further legal arguments on how to determine a causal connection between the drugs and the injuries claimed by the plaintiffs.
The involved parties must meet and set discovery and motion deadlines for the first two issues. The court will issue a comprehensive schedule after reviewing the proposals at a status conference on September 16, 2024.
The court’s strategy of addressing these pivotal issues early aims to streamline the litigation process by resolving critical legal questions that could potentially narrow or dismiss many claims. This is particularly true if the court finds that the drug labels were sufficient or that certain conditions like gastroparesis cannot be conclusively linked to these medications without objective testing.
Tomorrow marks the first anniversary of the first Ozempic lawsuit filed in the U.S. Currently, there are 117 claims in the multidistrict litigation brought against Ozempic’s maker, Novo Nordisk. The legal basis for these claims is that Novo Nordisk failed to warn Ozempic users about many of the possible side effects they might face.
While most of the complaints allege severe gastric issues, including stomach paralysis, other severe conditions are also being linked to Ozempic. For example, NAION, which can cause sudden vision loss, is a new concern. For more info on NAION, see our July 12th update, where we discussed the matter in depth. We expect this MDL to grow exponentially over the coming months and will monitor its progress.
A recent study conducted at Harvard University reviewed whether GLP-1 analog semaglutide medications like Ozempic may be linked to a vision loss condition known as nonarteritic anterior ischemic optic neuropathy (NAION). While more research is needed to confirm these findings, the study revealed that patients taking Ozempic and similar drugs might be four to eight times more likely to develop NAION than other patients using non-GLP-1 medications for diabetes and weight loss.
Patients with NAION experience a decreased blood supply to their optic nerves, which can lead to vision loss. The Harvard study looked at 710 Type 2 diabetic patients over 36 months. Those taking semaglutide had an NAION incidence rate of 8.9%, while patients using other types of diabetes medications only had a 1.8% incidence rate.
Over that same timeframe, the study reviewed 979 overweight or obese people, and those taking Ozempic (or any semaglutide drug) showed a 6.7% incidence rate of NAION vision loss, compared to only 0.8% of overweight people taking a medication that did not contain semaglutide.
The study ends by saying, “Conclusions and relevance: This study’s findings suggest an association between semaglutide and NAION. As this was an observational study, future study is required to assess causality.” So basically, they believe they are linked but need to figure out why.
As new research emerges, we will continue to monitor this potential connection between Ozempic use and vision loss. If you have any questions about using these medications and the side effects you are facing, reach out for a free consultation with our Ozempic vision loss lawsuit team.
Following Judge Pratter’s unfortunate passing, a new Judge has been assigned to oversee the Ozempic MDL. Judge Karen Spencer Marston, a seasoned former federal prosecutor, will now preside over the lawsuit in the Eastern District of Pennsylvania. Her first hearing in the MDL takes place today.
Due to the sudden death of Judge Pratter, Science Day in the Ozempic lawsuit has been canceled. The litigation is currently on hold while awaiting the assignment of a new Judge. Chief Judge Mitchell Goldberg of the Eastern District of Pennsylvania issued the order to cancel the event today.
The court has scheduled June 14th as “Science Day,” when both parties will present a snapshot of the scientific and medical evidence central to the Ozempic MDL. Though non-adversarial, attorneys will aim to sway the court early with their take on the science, including whether GLP-1 medications can cause gastroparesis and other serious gastrointestinal issues. It is expected that this MDL could involve nearly 40,000 cases.
Both sides are also working on finalizing the Plaintiff Fact Sheet (PFS), which will standardize the information required from plaintiffs. Rubris, an external company, will manage the submission and processing of these PFS forms and other electronic documents.
The number of lawsuits in the Ozempic MDL continues to grow, with plaintiffs alleging severe digestive side effects, including gastroparesis (stomach paralysis), bowel obstructions, and ileus (painful cramping, swelling, nausea, and difficulty digesting food). As of May 1st, the MDL now includes 87 cases tied to these side effects. If you’re considering legal action, the team at Lawsuit Legal News is here to answer your questions.
Defendants Novo Nordisk and Eli Lilly have officially responded to the plaintiffs’ claims in the Ozempic MDL, disputing the link between GLP-1RA drugs and stomach paralysis, along with allegations of aggressive marketing and failure to properly warn patients.
Their key argument is that the plaintiffs will struggle to prove causation in future trials, pointing out that diabetes itself can cause the same gastrointestinal issues being attributed to Ozempic and similar drugs. Plaintiffs, on the other hand, argue that the drugs increase the risk of conditions like gastroparesis, ileus, and bowel obstruction.
The lawsuit also challenges the aggressive marketing of Ozempic for weight loss despite the drug not being FDA-approved for that purpose. Manufacturers claim that healthcare providers are well aware of the risks, and it will be up to the court to determine whether the companies’ marketing practices were misleading about the severity of side effects and long-term use.
Why Choose Our Ozempic Stomach Paralysis Lawyers?
If you or a loved one has been diagnosed with Ozempic stomach paralysis, choosing the right Ozempic stomach paralysis attorney is necessary for the success of your claim. Our firm, Dolman Law Group Injury Lawyers, has a proven track record of success in handling personal injury cases, including those related to pharmaceutical negligence.
Here are some reasons why you should choose us to represent you:
- 400+ Settlements over pre-trial offer: Our firm has a strong record of successfully negotiating client settlements. We have obtained over 400 settlements higher than the initial pre-trial offer, ensuring our clients receive the compensation they deserve.
- $400+ Million in settlements: We have successfully recovered over $400 million in settlements for our clients, helping them alleviate the financial burdens associated with their injuries.
- 120+ combined years of experience: Our team of attorneys has over 120 years of combined experience, providing us with the knowledge and skills necessary to navigate the ins and outs of the legal process.
- “Best Lawyers” Best Lawyers of 2022: Our dedicated attorneys have been recognized by “Best Lawyers” as the best in their field, further solidifying our reputation for excellence.
- Avvo Clients Choice for Personal Injury: Avvo has recognized us as a Client’s Choice for Personal Injury due to our commitment to client satisfaction and high-quality legal representation.
- National Trial Lawyers Top 100 Lawyers: Our attorneys have been selected as part of the National Trial Lawyers Top 100 Lawyers, a prestigious recognition reserved for the most accomplished trial attorneys in the country.
Choosing our firm means trusting an experienced Ozempic stomach paralysis attorney who will fight vigorously on your behalf.
We serve clients throughout the United States and have many convenient office locations.
What Is Ozempic Stomach Paralysis?
Ozempic stomach paralysis, also known as Ozempic-induced gastroparesis, is when the stomach muscles become partially paralyzed, resulting in delayed gastric emptying. This condition can cause severe digestive issues and significantly impact the quality of life for those affected.
Patients diagnosed with Ozempic stomach paralysis often experience symptoms such as:
- Nausea
- Vomiting
- Bloating
- Early satiety (feeling full after eating small amounts of food)
- Abdominal pain
- Acid reflux
If you have been diagnosed with Ozempic stomach paralysis, promptly consult an Ozempic stomach paralysis attorney to understand your legal rights and pursue the compensation you deserve.
Ozempic Stomach Paralysis Compensation
If you have been diagnosed with Ozempic-induced gastroparesis and subsequent stomach paralysis, you may be entitled to financial recovery for your injuries and related losses. The value of your injury claim will depend on several factors, including:
- Medical Expenses: The cost of medical treatments, hospital stays, surgeries, medications, and ongoing therapies related to your Ozempic-induced gastroparesis.
- Lost Income: If your condition has prevented you from working or has resulted in a loss of income, you may be entitled to compensation for lost income.
- Pain and Suffering: The physical and emotional pain and suffering caused by Ozempic stomach paralysis may be factored into the award you receive.
- Future Expenses: If your condition requires long-term care or ongoing medical treatments, the anticipated future expenses may be part of your claim.
- Diminished Quality of Life: Ozempic stomach paralysis can significantly impact your quality of life. Damages may be available for the loss of enjoyment of life, inability to engage in certain activities, and other lifestyle changes.
You will want to hire a skilled Ozempic stomach paralysis attorney who can accurately assess the value of your claim and ensure that you receive the maximum amount possible. You’ll find that attorney at Dolman Law Group.
Factors that Determine the Value of Your Claim
Several factors will influence the value of your Ozempic stomach paralysis claim, including:
- The severity of your symptoms and their impact on your daily life
- The extent of medical treatment required for your condition
- The long-term prognosis and potential complications
- The degree of negligence or wrongdoing by the manufacturer of Ozempic
A well-versed Ozempic stomach paralysis attorney can evaluate the unique circumstances of your case and determine an appropriate amount.
What Causes Ozempic Stomach Paralysis
Ozempic stomach paralysis is primarily due to the medication Ozempic, which is prescribed to individuals with type 2 diabetes. The active ingredient in Ozempic, semaglutide, has been linked to an increased risk of gastroparesis and the subsequent development of Ozempic-induced stomach paralysis.
Gastroparesis is a condition characterized by delayed gastric emptying, where the stomach muscles do not contract effectively to move food through the digestive system. As a result, food remains in the stomach for an extended period, leading to symptoms such as nausea, vomiting, and bloating.
The exact mechanisms by which Ozempic causes stomach paralysis are still being studied. Still, it is believed to disrupt the normal functioning of the stomach muscles and interfere with the signals that control gastric emptying. There is no cure for gastroparesis.
What Is Pharmaceutical Negligence?
Pharmaceutical negligence refers to cases where individuals suffer harm or injury due to negligent actions by pharmaceutical companies, healthcare professionals, or any party involved in the manufacturing, distributing, or administering medication.
These cases can arise from various situations, such as defective drugs, improper labeling, incorrect prescriptions, or inadequate warnings about potential side effects.
When it comes to Ozempic stomach paralysis claims, pharmaceutical negligence may occur if the drug manufacturer fails to test the medication adequately or if they fail to warn patients and healthcare professionals about the potential risk of developing stomach paralysis.
Additionally, healthcare professionals may be accountable if they prescribe Ozempic without adequately assessing the patient’s medical history or if they fail to inform the patient about the potential side effects and risks associated with the medication.
According to Ozempic lawsuits, since the FDA approved Ozempic in 2017, Novo Nordisk, its manufacturer, has not included gastroparesis warnings in its prescription information until September 2023. The company warned about other Ozempic side effects but didn’t warn the public of the risk of severe gastroparesis.
Why Is Ozempic Being Sued for Failing to Warn About Gastroparesis?
Numerous lawsuits have been filed against the manufacturer of Ozempic, alleging that they failed to adequately warn patients and healthcare providers about the risk of developing gastroparesis and subsequent Ozempic stomach paralysis.
The lawsuits claim that the manufacturer knew or should have known about the potential side effects of the medication, including its association with gastroparesis. By failing to provide sufficient warnings, patients were not adequately informed of the risks associated with Ozempic, leading to injuries and damages.
If you have been diagnosed with Ozempic stomach paralysis, contact an Ozempic stomach paralysis attorney who can assess the viability of your case and get your claim started.
Who Qualifies to File an Ozempic Lawsuit?
If you or a loved one are suffering from stomach paralysis after taking Ozempic, you may be eligible to file a lawsuit and seek compensation for your injuries. There are a few key factors to determine if you qualify to file an Ozempic lawsuit.
First, you must have taken Ozempic and experienced stomach paralysis or other related complications. This can include symptoms such as severe abdominal pain, vomiting, bloating, or the inability to eat or drink.
Second, it’s important to establish a causal link between your use of Ozempic and the development of stomach paralysis. This can be done through medical documentation, such as medical records, diagnostic tests, and expert opinions from healthcare professionals.
Currently, you aren’t likely eligible to pursue an Ozempic stomach paralysis claim if you had gastric bypass surgery, gastric banding, or gastric sleeve surgery before beginning Ozempic treatment. If you are being treated for cancer, you also don’t qualify at this time.
Fighting for Compensation After Suffering Ozempic Stomach Paralysis
If you or a loved one have suffered from Ozempic-induced gastroparesis and subsequent stomach paralysis, be sure to have an Ozempic stomach paralysis attorney from our firm on your side. Here’s why:
- Experience: Our attorneys have a wealth of experience handling detailed personal injury cases, including those involving pharmaceutical negligence. We have the knowledge and skills to manage the legal process and fight for the compensation you deserve.
- Experience: We focus on personal injury cases and deeply understand the legal and medical aspects of Ozempic stomach paralysis. We will thoroughly investigate your case, gather evidence, and build a solid legal strategy to maximize your chances of success.
- Resources: Our firm has the resources necessary to support your case thoroughly. We work with experts, medical professionals, and investigators to strengthen your claim and properly evaluate all aspects of your injury.
- Negotiation skills: We are skilled negotiators and will aggressively pursue a fair settlement on your behalf. We aim to ensure that you receive adequate compensation for your injuries, medical expenses, lost income, and other damages.
- Trial experience: While many personal injury cases are resolved through settlements, we can take your case to trial if necessary. We have extensive trial experience and will fight tirelessly to protect your rights and interests.
What to Do After Sustaining Ozempic Stomach Paralysis Injuries
If doctors diagnosed you with Ozempic-induced gastroparesis and stomach paralysis:
- Seek medical attention: Consult a healthcare professional who can diagnose and document your condition. Follow their recommended treatment plan and attend all necessary medical appointments.
- Document your symptoms and treatment: Keep a record of all your symptoms, the treatments you have received, and any impact the condition has had on your daily life. This documentation can serve as evidence in your personal injury claim.
- Preserve evidence: If you still have any remaining Ozempic medication, preserve it as evidence. Additionally, gather evidence related to your diagnosis, such as prescriptions, pharmacy and medical records, test results, and doctor notes.
- Reach Out to an Ozempic Stomach Paralysis Attorney: Contact our firm to schedule a consultation with one of our experienced attorneys. We will review your case, assess its merits, and provide guidance on the best course of action.
Remember, time is of the essence when pursuing a personal injury claim. Statutes of limitations restrict the time you can file a lawsuit, so taking action promptly is imperative.
Were You Told You Have Ozempic Stomach Paralysis? Consult Dolman Law Group Injury Lawyers Today
If you or a loved one has been diagnosed with Ozempic stomach paralysis, seek legal representation to protect your rights and pursue the compensation you deserve. Our knowledgeable Ozempic stomach paralysis attorneys at Dolman Law Group Injury Lawyers have a proven track record of successfully handling complex personal injury cases involving pharmaceutical negligence.
Contact us today at 833-552-7274 or online for your free consultation and take the first step towards securing your future.